Bausch Health Companies Inc. (TSX:BHC)
6.25
-0.04 (-0.64%)
Jun 4, 2025, 11:58 AM EDT
Bausch Health Companies Revenue
Bausch Health Companies had revenue of $2.26B USD in the quarter ending March 31, 2025, with 4.92% growth. This brings the company's revenue in the last twelve months to $9.73B, up 8.53% year-over-year. In the year 2024, Bausch Health Companies had annual revenue of $9.63B with 9.91% growth.
Revenue (ttm)
$9.73B
Revenue Growth
+8.53%
P/S Ratio
0.17
Revenue / Employee
$470.10K
Employees
20,700
Market Cap
2.32B CAD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.63B | 868.00M | 9.91% |
Dec 31, 2023 | 8.76B | 633.00M | 7.79% |
Dec 31, 2022 | 8.12B | -310.00M | -3.68% |
Dec 31, 2021 | 8.43B | 407.00M | 5.07% |
Dec 31, 2020 | 8.03B | -574.00M | -6.67% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
dentalcorp Holdings | 1.58B |
Sienna Senior Living | 896.45M |
Green Thumb Industries | 1.64B |
Extendicare | 1.47B |
Cronos Group | 179.08M |
Trulieve Cannabis | 1.71B |
WELL Health Technologies | 990.34M |
Curaleaf Holdings | 1.89B |
Bausch Health Companies News
- 5 hours ago - Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States - Business Wire
- 14 days ago - Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players - Allergan, Bausch Health, Bloomage Biotechnology, and Galderma - GlobeNewsWire
- 14 days ago - Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States - Business Wire
- 20 days ago - Bausch Health Announces 2025 Annual Meeting of Shareholder Results - Accesswire
- 21 days ago - Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States - Business Wire
- 26 days ago - Bill Ackman Took A $4 Billion Hit But Says 'Making Progress Each Day' Was Key To Recovering From The Valeant Disaster - Benzinga
- 4 weeks ago - Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens - Business Wire
- 4 weeks ago - Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization - Accesswire